The groundbreaking rise of Viagra has long been a symbol of pharmaceutical success, however its position within the broader industry now triggers questions about long-term yields . Copycat versions are diminishing exclusivity , causing concerns that betting on companies closely tied to Viagra's previous position could be a problematic strategy, esp